Navigation Links
Biopharm Insight’s Respiratory Disease Report Highlights Key Drugs Coming Up for Approval or in Late-Stage Development
Date:11/6/2013

Norwood, MA (PRWEB) November 06, 2013

BioPharm Insight’s Respiratory Disease Report covers key drugs in development in this competitive therapeutic sector. The report is based on primary research and interviews conducted with numerous physicians, investigators and key opinion leaders at the recent European Respiratory Society Annual Congress 2013 in Barcelona, Spain.

In discussing the Respiratory Disease Report, Kirsty Barnes, Biopharm Insight’s Editor EMEA, said, “The report is another example of why decision makers in pharmaceutical R&D or the investment side of drug development rely on BioPharm Insight’s independent investigative journalism, market analytics and key industry contacts to gain competitive insight.”

Some highlights and key takeaways from the report:

  •     Competitive landscape of LABA/LAMA combinations in development to treat COPD
  •     Novartis'combination drug Ultibro Breezhaler for chronic obstructive pulmonary disease (COPD) and US market outlook
  •     Forest and Almirall’s aclidinium bromide/formoterol combination
  •     Boehringer's Spiriva Respimat (tiotropium) mist inhaler in COPD
  •     In idiopathic pulmonary fibrosis (IPF), Novartis’ QAX576, an anti-IL-13 in Phase II development, has been quietly terminated
  •     In asthma, GlaxoSmithKline and partner Theravance are still considering their strategy to progress Breo Ellipta (fluticasone furoate/vilanterol) for US approval.
  •     In pulmonary arterial hypertension (PAH), Actelion will need to get experts engaged in the discussion on Opsumit’s (macitentan) EU pricing. EU approval decision is expected YE.
  •     Bayer is in the planning stages of a Phase IIIb study (RESPITE) evaluating riociguat in PAH for those patients insufficiently treated with phosphodiesterase-5 inhibitors.
  •     PTC Therapeutics' ataluren for cystic fibrosis caused by nonsense mutations (nmCF).

Subscribers to BioPharm Insight received the Respiratory Report on October 15.

Non-subscribers, download the report.

About BioPharm Insight

BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.

About Infinata, Inc.

Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253

Read the full story at http://www.prweb.com/releases/2013/11/prweb11300052.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. BioPharm Systems Named to the 2012 Lead411 Technology 200 List
2. BioPharm Systems to Host Webinar on Using iHelp in Oracle’s Siebel Clinical Trial Management System
3. BioPharm Systems to Host Webinar on Clinical Trial Supply Management with Siebel CTMS
4. Nine Lives Media Names BioPharm Systems to the MSPmentor 501
5. BioPharm Systems Unveils Study Data Mapper to Simplify the Preparation and Reporting of Clinical Data
6. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
7. Therapure Biopharma Inc. Awarded US Government Contract for Development of Anti-Nerve Gas Agent
8. World Antibiotic Resistance Market Saw Big Changes in Last Five Years, According to Biopharm Reports Study Available at MarketPublishers.com
9. Mass Spectrometry Marketplace Discussed by Biopharm Reports in In-demand Research Study Available at MarketPublishers.com
10. Study says children exposed to tobacco smoke face long-term respiratory problems
11. Study shows antibiotic improves respiratory function in lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has ... 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and have ... workout. , After a successful launch in Sweden last year, the next generation ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas ... Indiana where she works in a daycare and looks for inspiration in the local ... Faith Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and ... simple and achievable answer. “The Land of More and More” is the creation of ... Angola, Indiana where he works with the children’s ministry department. , Michael says ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Management System: an On-demand E-learning system for Clinical and Regulatory education for ... is based on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... This report on the opioid induced constipation ... the global market. Large number of chronic pain sufferers ... is a major side effect of consumption of opioid ... therapy has been prescribed to treat opioid induced constipation. ... and growing awareness about the therapy are the major ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  Abaxis, Inc. ... manufacturing point-of-care blood analysis instruments and consumables for the ... call to discuss its financial results for the third ... call will be at 4:15 p.m. ET on Thursday, ... for the third quarter fiscal year 2017 after the ...
Breaking Medicine Technology: